| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-106 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于2026年度开展金融衍生品交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：结合资金管理要求和日常经营需要，蓝帆医疗股份有限公司（以下 简称"公司"）及子公司拟开展的金融衍生品交易业务主要包括但不限于远期结售汇、 结构性远期、外汇掉期、货币期权、利率掉期等产品及上述产品的组合。 2、投资金额及期限：公司及子公司根据实际需要选择业务币种，2026 年度拟开展 套期保值业务预计动用的保证金和权利金上限（包括为交易而提供的担保物价值、为 应急措施所预留的保证金等）为等额人民币 0.55 亿元，任一交易日持有的最高合约价 值不超过等额人民币 15.00 亿元。额度使用期限自董事会审议通过之日起 12 个月内有 效，额度使用期限内任一时点的交易金额（含上述交易的收益进行再交易的相关金额） 不超过上述额度，实际涉及缴纳的保 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-098 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于子公司增资扩股引入外国产业投资者的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、交易概述 蓝帆医疗股份有限公司（以下简称"公司"）于 2024 年 6 月 19 日召开第六届董 事会第十一次会议，审议通过了《关于子公司增资扩股引入外国产业投资者的议案》， 公司的全资子公司山东蓝帆健康科技有限公司（以下简称"山东健康科技"）以增资 扩股方式引入泰国产业投资者 Hua Kee Co., Ltd.（以下简称"HKG"）。HKG 按照交 易前估值人民币 211,645.73 万元以现金方式增资 2 亿美元（折合人民币约 142,072.00 万元），认购山东健康科技新增注册资本人民币 139,178.88 万元，剩余人民币 2,893.12 万元计入资本公积。本次增资款将分两个阶段缴付，每个阶段付款 1 亿美元（折合人 民币约 71,036. ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-103 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于继续租赁关联方房屋及停车位的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、关联交易概述 蓝帆医疗股份有限公司（以下简称"公司"、"本公司"或"蓝帆医疗"）承租了淄 博恒辉企业管理有限公司（以下简称"淄博恒辉"，原名为淄博恒辉资产管理有限公司） 拥有的房屋一处及所附属停车位 20 个作为总部办公中心，合同约定租赁期限为 13 年， 从 2020 年 1 月 4 日至 2033 年 10 月 31 日，租赁费用前 5 年按照 60 万元/年支付，第 6 年后双方以市场价为依据协商调整。该项关联交易事项已经公司 2020 年 3 月 17 日召 开的第四届董事会第三十三次会议和 2022 年 12 月 13 日召开的第五届董事会第二十九 次会议审议通过。 根据《房屋租赁合同》约定和公司实际需要，鉴于该合同履行将满 6 年，公司向 淄博恒辉发送了 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-109 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 3、会议召开的合法、合规性：本次召开股东会的议案经公司第六届董事会第三 十五次会议审议通过。本次股东会的召集、召开符合《中华人民共和国公司法》《深 圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《蓝帆医疗股 份有限公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 29 日（星期一）14:00 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 经蓝帆医疗股份有限公司（以下简称"公司"或"本公司"）第六届董事会第三 十五次会议审议通过，公司决定于 2025 年 12 月 29 日召开 2025 年第七次临时股东 会，现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第七次临时股东会 2、股东会的召集人：董事会 蓝帆医疗股份有限公司 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-099 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 1、审议并通过了《关于山东蓝帆健康科技有限公司收购淄博蓝帆健康科技有限公 司及淄博蓝帆防护用品有限公司100%股权的议案》； 为进一步盘活公司健康防护事业部丁腈手套业务，切实运用好外国产业投资者投 入合资公司的增资款项，在新的国际贸易形势下变"新建增量"加剧供需失衡为"整 合存量"全面提升效率，提振公司丁腈手套业务的整体运营水平与市场竞争力，同意 公司的控股子公司山东蓝帆健康科技有限公司（即合资公司，以下简称"山东健康科 技"）以自有资金8亿元收购公司全资子公司淄博蓝帆健康科技有限公司（以下简称"淄 博健康科技"）及淄博蓝帆防护用品有限公司（以下简称"淄博蓝帆防护"）100%股权。 本次交易完成后，淄博健康科技、淄博蓝帆防护将由公司 100%持股的子公司变为 由公司的控股子公司山东健康科技 100%持股的子公司，仍将继续纳入公司合并报表范 围。 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 ...

Core Viewpoint - The company plans to engage in financial derivatives trading to mitigate foreign exchange and interest rate risks for the year 2026 [1] Group 1: Financial Derivatives Trading - The company and its subsidiaries intend to conduct financial derivatives trading, including forward foreign exchange contracts and foreign exchange swaps [1] - The maximum margin and premium to be utilized for these transactions is set at 55 million yuan, with the highest contract value held on any trading day not exceeding 1.5 billion yuan [1] - The validity period for the usage of these trading limits is 12 months from the date of approval by the board of directors [1] Group 2: Risk Management - The company has analyzed market and liquidity risks associated with the trading activities and has established corresponding control measures [1] - Transactions will be conducted with qualified financial institutions, using the company's own funds [1]

本资产评估报告依据中国资产评估准则编制 山东蓝帆健康科技有限公司拟股权收购涉及的 淄博宏达热电有限公司股东全部权益价值 资产评估报告 格律沪评报字（2025）第 233 号 共一册第一册 格律（上海）资产评估有限公司 GeLv (Shanghai) Assets Appraisal Co., Ltd 2025 年 12 月 10 日 | 声明 1 | | --- | | 资产评估报告摘要 2 | | 资产评估报告正文 3 | | 一、委托人及其他资产评估报告使用人 3 | | 二、评估目的 5 | | 三、评估对象和评估范围 5 | | 四、价值类型及其定义 8 | | 五、评估基准日 8 | | 六、评估依据 8 | | 七、评估方法 10 | | 八、评估程序实施过程和情况 14 | | 九、评估假设 15 | | 十、评估结论 16 | | 十一、特别事项说明 17 | | 十二、资产评估报告使用限制说明 20 | | 十三、资产评估报告日 20 | | 十四、资产评估专业人员签名和资产评估机构印章 21 | | 资产评估报告附件 22 | 山东蓝帆健康科技有限公司拟股权收购涉及的 淄博宏达热电有限公司 ...

Group 1 - Lu Kang Pharmaceutical plans to increase capital by 109 million yuan to its wholly-owned subsidiary Bio-Pesticide Company and 27 million yuan to Ze Run Company, aiming to expand its pesticide and sales sectors [1] - Hui Green Ecology intends to sell two properties in Ningbo for 12.52 million yuan, expecting a net profit impact of approximately 6.23 million yuan from the transaction [2] - Tianyuan Co., Ltd. plans to invest 185 million yuan in an intelligent upgrade project for its titanium dioxide production facilities [3] Group 2 - Metro Design has received approval from the Shenzhen Stock Exchange for its share issuance to acquire 100% equity of Guangzhou Metro Engineering Consulting Co., Ltd. for 511 million yuan [4] - South Network Energy announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 0.07 yuan per 10 shares [5] - Qibin Group plans to establish two wholly-owned subsidiaries in Shenzhen with a registered capital of 100 million yuan each [6] Group 3 - All New Good received an administrative regulatory decision from the Shenzhen Securities Regulatory Bureau due to issues in financial accounting and information disclosure [7] - Luokai Co., Ltd. announced that its shareholders plan to reduce their holdings by up to 3% of the company's shares [8][9] - Jincheng Pharmaceutical's actual controller received an administrative penalty from the CSRC for stock manipulation, leading to the resignation of the chairman [10] Group 4 - Yicheng New Energy intends to acquire a 7.69% stake in Kaifeng Times for 10 million yuan, enhancing its strategic development [11] - Yujing Co., Ltd. signed a sales contract worth approximately 28.6 million USD with an overseas photovoltaic company [12] - Nuocheng Jianhua's TRK inhibitor, Zoltracitinib, has been approved for market entry in China [13] Group 5 - Nandu Power announced that its controlling shareholder is planning a change in control, leading to a temporary suspension of its stock [14] - Xinxing Casting plans to acquire 100% equity of China Resources Steel for 1.244 billion yuan to focus on special steel development [15] - Xinlitai is planning to issue H-shares and list on the Hong Kong Stock Exchange [16] Group 6 - Blue Fan Medical's subsidiary received approval for a new medical device, the coronary artery scoring balloon dilation catheter [18] - China Iron & Steel plans to establish a joint venture with several companies to provide new energy transportation solutions with a registered capital of 500 million yuan [19] - Jifeng Technology intends to sign a cooperation framework agreement with Dongtai Lianfei for a total transaction amount not exceeding 100 million yuan [20] Group 7 - Zhongwei Electronics announced a change in its actual controller, with stock resuming trading [21] - Weihong Co., Ltd. plans to reduce its holdings by up to 1.15% of the company's shares [22] - Te Fa Information received a criminal judgment related to a fraud case involving the acquisition of Shenzhen Te Fa Dongzhi Technology Co., Ltd. [23] Group 8 - Sunshine Dairy's controlling shareholder's concerted action plans to reduce holdings by up to 3% of the company's shares [24] - Meikailong reported that Taobao Holdings and New Retail Fund collectively reduced their H-shares by 30.616 million shares [25] - Xinjubang plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [26] Group 9 - Beite Technology's application for issuing A-shares to specific objects has been approved by the Shanghai Stock Exchange [28] - Victory Energy's controlling shareholder is planning a change in control, with stock resuming trading [29] - Jiutian Pharmaceutical signed a patent and technology transfer agreement for a small molecule analgesic drug project, with a total transfer fee not exceeding 400 million yuan [29]

Core Viewpoint - The approval of the "Coronary Scoring Balloon Dilatation Catheter" by the National Medical Products Administration (NMPA) represents a significant advancement for the company in providing effective solutions for complex coronary artery diseases [1][2]. Product Information - The product, named "Star Scar," features a unique spiral triangular scoring wire that allows for 360° efficient pressure-focused dilation [1]. - It is the only coronary scoring balloon with up to four scoring wires, providing a larger scoring area and a rated burst pressure (RBP) of up to 20 atm, enhancing safety during expansion [1]. - The device is particularly advantageous for treating calcified and high-resistance complex lesions, offering a safer and more ideal choice for coronary intervention [1]. Impact on the Company - The successful approval of the Star Scar catheter not only provides a precise and efficient pre-dilation option for complex coronary artery lesions but also completes the strategic puzzle for the company's cardiovascular division in constructing a "PCI optimization full-link solution" [2]. - This development is expected to positively influence the company's operational growth by enabling a comprehensive solution for both simple and complex lesions in PCI treatments [2].

Core Viewpoint - Blue Sail Medical (002382.SZ) has received the medical device registration certificate from the National Medical Products Administration (NMPA) for its self-developed and produced Class III medical device, the "Coronary Scoring Balloon Dilatation Catheter" (branded as "Star Scar™") [1] Group 1: Product Features - The Star Scar™ catheter features a unique spiral-wound triangular scoring wire that allows for 360° efficient pressure-focused dilation [1] - It is the market's highest with four scoring wires, providing a larger scoring area and a rated burst pressure (RBP) of up to 20 atm, which offers a higher safety expansion margin [1] - The device excels in reducing the incidence of dissection and optimizing vascular preparation, particularly advantageous for complex lesions such as calcification [1] Group 2: Market Implications - The introduction of the Star Scar™ catheter provides a safer and more ideal option for coronary intervention treatments [1]